Technology evaluation: Matuzumab, Merck KGaA.
Merck KGaA is developing matuzumab, a fully humanized epidermal growth factor receptor (EGFR)-specific monoclonal antibody, as a potential treatment for EGFR-bearing tumors. Matuzumab is currently undergoing phase II clinical trials for gastric, cervical, pancreatic and ovarian cancers.
Kim
Tracy
T
tracy.e.kim@kp.org
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes; D008297:Male; D010051:Ovarian Neoplasms / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000628:therapy; D016499:Radioimmunotherapy / Q000379:methods; D013274:Stomach Neoplasms / Q000628:therapy; D002583:Uterine Cervical Neoplasms / Q000628:therapy
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D066246:ErbB Receptors